Skip to main content
IMS Events Main banner
Back

    Thomas Martin, MD

    Clinical Professor of Medicine
    Department of Hematology, University of California at San Francisco, San Francisco, CA, USA
    San Francisco, United States

    Thomas G. Martin III, MD, is Director of the Hematology Malignancies Research Committee and Co-Director of the Myeloma Program at UCSF Helen Diller Family Comprehensive Cancer Center.

    Dr. Martin earned his medical degree at the University of Connecticut School of Medicine. He completed internship and residency programs at Harbor‐UCLA Medical Center and a fellowship in hematology/oncology at UCSF Medical Center, where he was promoted to Adjunct Professor of Medicine in the Division of Hematology and Oncology. Dr. Martin later was appointed Assistant Professor of Medicine at The University of Texas MD Anderson Cancer Center. After several years, he joined the faculty at UCSF, where he continues to serve as Professor of Clinical Medicine in the Adult Hematology, Bone Marrow Transplantation and Cellular Therapies Program. He is also currently the interim Co-Chief of the Division of Hematology/Oncology at UCSF.

    Dr. Martin’s research focuses on investigating novel treatments for multiple myeloma. This includes early‐phase trials of new drugs, novel combinations, and therapeutics to use with bone marrow transplantation. He has a special interest in antibody therapy for myeloma, as well as novel immunotherapies for myeloma.

    A Diplomate of the American Board of Internal Medicine with subspecialty certification in hematology, Dr. Martin is a member of the American Society for Blood and Marrow Transplantation, the American Academy for the Advancement of Science, and the American Society of Hematology. Dr. Martin has authored numerous articles in the peer‐reviewed literature. Additionally, he is a teacher, mentor, and a frequently invited speaker.

    Dr. Martin is a member of the NCCN Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström's Macroglobulinemia Panel, and a member of the International Myeloma Foundation Advisory Committee.

    Disclosure information not submitted.

    Presentation(s):